National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

 

NCPE Assessment Process Complete
Rapid review commissioned 03/07/2019
Rapid review completed 19/07/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.